

PRESS RELEASE

Novelogs Biotechnology Inc. receives Government of Canada support for the development of new cancer treatment.

VANCOUVER, BC - January 15, 2015 – Novelogs Biotechnology Inc. reports that it has received a financial contribution from the National Research Council of Canada (NRC) Industrial Research Assistance Program (IRAP) of up to \$134,800 to help support further development of Novelogs' new approach to fighting cancer. The objective of the IRAP-sponsored project is to complete a proof-of-concept study and to transition the project into pre-clinical development by 2016.

The proprietary technology behind Novelogs' innovation involves discovery and development of monoclonal antibodies that target soluble decoy proteins that are involved with the devastating immune system suppression associated with cancer progression. It is predicted that this new therapy will broadly treat many types of cancers and will do so in a less toxic fashion without inducing debilitating side-effects. Patients should not get sick to get better, as it stimulates the body's own immune system to fight cancer more naturally. As modern cancer therapies typically include treatment with several drugs, we anticipate exploring the potential for rational approaches to combine our drug with other frontline therapeutics in order to maximize treatment outcomes for cancer patients.

NRC-IRAP's ongoing technical and business advice, along with its financial contribution, is helping to guide and optimize the overall research endeavour in a timely fashion. It is anticipated that a lead development candidate antibody will be selected in 2015, which will not only help validate our concept but also justify our drive towards clinical trials in cancer patients.

About Novelogs Biotechnology Inc.

Novelogs Biotechnology Inc. is an early-stage life sciences company dedicated to developing innovative cancer treatments that harness the power of the immune system to help eradicate tumors more naturally. Our immunotherapy concepts focus on development of antibody therapeutics and medical devices and are designed to treat multiple cancer types and to have fewer side effects than traditional cancer therapies. We are currently exploring partnership opportunities with larger biotechnology and pharmaceutical companies that are interested in commercializing new treatments in this exciting area of cancer drug development. Novelogs has one mission in mind. We want to create better cancer treatments. www.novelogs.com

Novelogs Biotechnology Inc. is a privately-owned corporation operating in Vancouver, Canada.

Media contact:
Elaine Allison
info@novelogs.com
(604) 723-7774